Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.21M | $1.69M | $1.41M | $2.91M | — | — | — | $1.70M | $10.1M | $75.4M |
| Revenue growth | — | 39.7% | -16.9% | 106.7% | — | — | — | — | 496.0% | 644.9% |
| Operating income | — | -$23.4M | -$57.5M | -$146M | -$168M | -$141M | -$143M | -$180M | -$241M | -$271M |
| Operating margin | — | -1383.2% | -4089.1% | -5022.8% | — | — | — | -10583.1% | -2385.6% | -358.9% |
| Net income | -$12.6M | -$19.7M | -$44.8M | -$124M | -$142M | -$142M | -$149M | -$208M | -$221M | -$288M |
| Net margin | -1035.5% | -1165.2% | -3180.6% | -4258.9% | — | — | — | -12272.3% | -2180.5% | -381.4% |
| EPS (diluted) | -$1.26 | -$1.43 | -$1.42 | -$2.88 | -$2.76 | -$1.97 | -$1.57 | -$1.20 | -$0.86 | -$1.08 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.85M | -$16.4M | -$31.5M | -$101M | -$118M | -$118M | -$112M | -$146M | -$206M | -$284M |
| Capital expenditures | $1.85M | $2.88M | $9.12M | $18.3M | $14.7M | $8.86M | $10.8M | $11.0M | $22.1M | $19.0M |
| Free cash flow | -$11.7M | -$19.2M | -$40.7M | -$120M | -$132M | -$127M | -$123M | -$157M | -$228M | -$303M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $28.1M | $137M | $218M | $211M | $154M | $310M | $269M | $240M | $227M | $104M |
| Total assets | — | $149M | $254M | $304M | $294M | $406M | $364M | $375M | $783M | $589M |
| Total liabilities | — | $6.06M | $21.6M | $48.7M | $84.2M | $92.2M | $92.9M | $264M | $355M | $411M |
| Long-term debt | — | $763K | $285K | $0.00 | — | — | — | — | — | — |
| Shareholders' equity | $30.7M | $143M | $233M | $255M | $210M | $313M | $299M | $111M | $427M | $178M |
| Retained earnings | — | -$47.9M | -$113M | -$237M | -$379M | -$521M | -$558M | -$879M | -$1.10B | -$1.39B |
| Shares (wtd avg diluted) | — | — | — | 43.1M | 51.6M | 72.1M | 95.0M | 174M | 255M | 266M |
Every figure is extracted from Autolus Therapeutics plc’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.